Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

1.155 -0.035 (-2.94%)
Streaming Delayed Price Updated: 3:29 PM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,455,116
Open 1.220
Bid (Size) 1.150 (40)
Ask (Size) 1.160 (44)
Prev. Close 1.190
Today's Range 1.130 - 1.230
52wk Range 0.8621 - 3.780
Shares Outstanding 142,183,418
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-47.5%
-47.5%
1 Month
-18.7%
-18.7%
3 Month
-19.2%
-19.2%
6 Month
-46.5%
-46.5%
1 Year
-48.4%
-48.4%

More News

Read More
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics's Earnings Outlook
Via Benzinga
Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For May 13, 2025
Via Benzinga
Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For March 13, 2025
Via Benzinga
Allogene Therapeutics Announces Participation in March Investor Conference
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Short Interest Reportedly Near 5-Year Lows Amid Growing Retail Optimism: Analyst Sees CAR-T Therapy Promise
Via Stocktwits
Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Tuesday's session: gap up and gap down stocks
Via Chartmill
Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins
Via FinancialNewsMedia
Topics Artificial Intelligence
Friday's session: top gainers and losers
Via Chartmill
What's going on in today's session
Via Chartmill
Friday's session: gap up and gap down stocks
Via Chartmill
Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Announces Participation in February Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
From Allogene Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Allogene Therapeutics, Inc. - Common Stock publicly traded?
Yes, Allogene Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Allogene Therapeutics, Inc. - Common Stock trade on?
Allogene Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Allogene Therapeutics, Inc. - Common Stock?
The ticker symbol for Allogene Therapeutics, Inc. - Common Stock is ALLO on the Nasdaq Stock Market
What is the current price of Allogene Therapeutics, Inc. - Common Stock?
The current price of Allogene Therapeutics, Inc. - Common Stock is 1.155
When was Allogene Therapeutics, Inc. - Common Stock last traded?
The last trade of Allogene Therapeutics, Inc. - Common Stock was at 07/07/25 03:29 PM ET
What is the market capitalization of Allogene Therapeutics, Inc. - Common Stock?
The market capitalization of Allogene Therapeutics, Inc. - Common Stock is 164.22M
How many shares of Allogene Therapeutics, Inc. - Common Stock are outstanding?
Allogene Therapeutics, Inc. - Common Stock has 164M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.